Global Interventional Oncology Market Anticipates Explosive Growth, Forecasted at $8.06 Billion by 2034 - Regional Insights for Products, Cancer Types, and End-users
12 mars 2024 12h39 HE
|
Research and Markets
Dublin, March 12, 2024 (GLOBE NEWSWIRE) -- The "Global Interventional Oncology Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The global...
CURIUM ANNUNCIA LE PRIME DOSI COMMERCIALI IN ITALIA DI PYLCLARI® - UN INNOVATIVO TRACCIANTE PET 18F-PSMA INDICATO NEI PAZIENTI CON TUMORE ALLA PROSTATA
07 mars 2024 08h51 HE
|
Curium
Parigi, Francia, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, leader mondiale nella medicina nucleare, ha annunciato oggi la vendita delle prime dosi commerciali di PYLCLARI® in Italia. PYLCLARI®...
Curium Announces First Commercial Doses in Italy of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
07 mars 2024 08h51 HE
|
Curium
PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy. PYLCLARI® (INN:...
Arvinas to Participate in Upcoming Investor Conferences
04 mars 2024 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Celcuity to Participate in Cowen’s 44th Annual Health Care Conference
28 févr. 2024 07h05 HE
|
Celcuity Inc.
MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
27 févr. 2024 07h00 HE
|
Arvinas Inc.
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the...
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer
22 févr. 2024 16h05 HE
|
Celcuity Inc.
MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that the first patient...
Curium Announces Submission of the Marketing Authorization Application for PYLCLARI®, an Innovative (18F)-PSMA PET Tracer Indicated in Adults With Prostate Cancer to Swissmedic
22 févr. 2024 06h19 HE
|
Curium
PARIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the marketing authorization application for PYLCLARI® (INN: Piflufolastat (18F) formerly...
Arvinas Announces Chief Financial Officer Transition
20 févr. 2024 16h05 HE
|
Arvinas Inc.
- Sean Cassidy leaving Arvinas as of February 29, 2024 - - Randy Teel, Ph.D. to assume the role of interim Chief Financial Officer - NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas,...
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
20 févr. 2024 07h05 HE
|
Celcuity Inc.
MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the...